Novo Nordisk commits USD 200 million to strengthen diabetes care through long-term partnerships, prevention programs and healthcare access in developing countries.
Johnson & Johnson (J&J) has taken another significant step in expanding Caplyta’s bipolar treatment potential, securing its second positive Phase 3 trial result for bipolar mania.
India extends the Medical Device PLI Scheme to 2036, offering manufacturers greater investment flexibility and incentives for domestic component manufacturing.
Divi's Labs bets on peptide growth with a Rs 2,000 crore expansion to strengthen innovative pharmaceutical manufacturing and meet customer demand.
India’s mental health crisis reflects more than limited treatment access, with stigma, affordability and professional shortages widening the care gap.
AstraZeneca is strengthening its bacterial vaccine pipeline through the acquisition of US biotechnology company Omniose.
HHS has introduced an interim peptide compounding policy covering six substances, creating new opportunities and raising pharmaceutical safety concerns.
The Bulk Drug PLI Scheme is set for a proposed Rs 7,000 crore revamp to address India's pharmaceutical manufacturing challenges.
CDMO growth is becoming a central focus for BDR Pharma as it expands its pharmaceutical manufacturing capabilities and international business opportunities.
Alembic Pharmaceuticals' USFDA approval strengthens its position in the generic eye drops market through a specialised ophthalmic formulation.